Maternal and Neonatal Circulating Markers of Metabolic and Cardiovascular Risk in the Metformin in Gestational Diabetes (MiG) Trial
Open Access
- 13 February 2013
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 36 (3) , 529-536
Abstract
OBJECTIVE This study was designed to compare glucose, lipids, and C-reactive protein (CRP) in women with gestational diabetes mellitus treated with metformin or insulin and in cord plasma of their offspring and to examine how these markers relate to infant size at birth. RESEARCH DESIGN AND METHODS Women with gestational diabetes mellitus were randomly assigned to metformin or insulin in the Metformin in Gestational Diabetes trial. Fasting maternal plasma glucose, lipids, and CRP were measured at randomization, 36 weeks’ gestation, and 6–8 weeks postpartum as well as in cord plasma. Women with available cord blood samples (metformin n = 236, insulin n = 242) were included. RESULTS Maternal plasma triglycerides increased more from randomization to 36 weeks’ gestation in women treated with metformin (21.93%) versus insulin (9.69%, P < 0.001). Maternal and cord plasma lipids, CRP, and neonatal anthropometry did not differ between treatments. In logistic regression analyses adjusted for confounders, the strongest associations with birth weight >90th centile were maternal triglycerides and measures of glucose control at 36 weeks. CONCLUSIONS There were few differences in circulating maternal and neonatal markers of metabolic status and no differences in measures of anthropometry between the offspring of women treated with metformin and the offspring of women treated with insulin. There may be subtle effects of metformin on maternal lipid function, but the findings suggest that treating gestational diabetes mellitus with metformin does not adversely affect lipids or CRP in cord plasma or neonatal anthropometric measures.Keywords
This publication has 40 references indexed in Scilit:
- Maternal age, ethnicity and gestational diabetes mellitusMidwifery, 2012
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) StudyDiabetes Care, 2012
- Dysregulation of Placental Endothelial Lipase in Obese Women With Gestational Diabetes MellitusDiabetes, 2011
- Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)Diabetes Care, 2011
- Establishing consensus criteria for the diagnosis of diabetes in pregnancy following the HAPO studyAnnals of the New York Academy of Sciences, 2010
- Maternal Lipids as Strong Determinants of Fetal Environment and Growth in Pregnancies With Gestational Diabetes MellitusDiabetes Care, 2008
- Reference values for clinical chemistry tests during normal pregnancyBJOG: An International Journal of Obstetrics & Gynaecology, 2008
- Transfer of metformin across the dually perfused human placental lobuleAmerican Journal of Obstetrics and Gynecology, 2006
- The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic reviewJournal of Internal Medicine, 2004
- Fetal macrosomia related to maternal poorly controlled type 1 diabetes strongly impairs serum lipoprotein concentrations and compositionJournal of Clinical Pathology, 2000